Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
HER2 Gene MutationAdenocarcinoma Lung Stage IV
Interventions
DRUG

Poziotinib

A cycle of study treatment is defined as 28 days.

Trial Locations (1)

Unknown

Korean Association for the Study of Targeted Therapy, Seoul

All Listed Sponsors
collaborator

Konkuk University Medical Center

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Kosin University Gospel Hospital

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Chungnam National University Hospital

OTHER

lead

Korean Association for the Study of Targeted Therapy

OTHER

NCT02979821 - Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | Biotech Hunter | Biotech Hunter